Opyl signs service level agreement with Southern Clinical Development Consulting

Latest News

AI-driven clinical trial design and optimisation company Opyl (ASX: OPL) has signed a service-level agreement with Southern Clinical Development Consulting (Southern CDC).

Opyl said the agreement licenses its TrialKey platform to Southern CDC, enhancing their clinical trial support and optimisation capabilities. OPL will receive fees for its services.

Southern CDC supports drug development across key therapeutic areas, including oncology, immunology, neurology, ophthalmology and infectious diseases, through early and late-stage clinical trials.

Opyl will provide AI-powered insights via the TrialKey platform, offering predictive modelling and validation to support trial design and planning. It will receive a specified fee for each report under the agreement. TrialKey will assist Southern CDC in trial design, site feasibility, and patient recruitment strategies to support informed, data-driven decisions.

Opyl executive chairman Saurabh Jain said, “We’re pleased to see Southern CDC adopt our TrialKey platform, taking a step toward our broader strategy of partnering with CROs globally. Our goal is to make TrialKey an essential tool in every CRO’s service offering, providing the kind of data-driven insights that both CROs and their clients increasingly rely on. As more CROs look to optimise trial design and efficiency, we believe TrialKey will become a standard, indispensable part of clinical trial management worldwide.”

Dr Khalid Abubaker, the chief operating officer of Southern CDC, added, “At Southern CDC, we are committed to advancing drug development and enhancing patient treatment through our tailored solutions. TrialKey’s advanced analytics, unlocks new opportunities to refine trial designs, optimise site selections, and develop recruitment strategies that truly meet patient needs. This partnership empowers us to accelerate clinical trials for our sponsors, effectively addressing unmet medical needs with agility and precision. We’re excited to jointly expedite the development of life-changing treatments, where every day counts.”